The ADIPOQ gene encodes adiponectin, a hormone predominantly secreted by adipose tissue that plays a critical role in regulating glucose metabolism, insulin sensitivity, and inflammatory responses. As a key adipokine, adiponectin exists in multiple oligomeric forms (low-, medium-, and high-molecular-weight complexes) and exerts systemic effects through binding to receptors AdipoR1 and AdipoR2. Reduced circulating adiponectin levels are associated with obesity, type 2 diabetes, cardiovascular diseases, and metabolic syndrome, making it a biomarker of interest in metabolic research. Antibodies targeting ADIPOQ/adiponectin are essential tools for detecting and quantifying this protein in biological samples. They are widely used in immunoassays such as ELISA, Western blotting, and immunohistochemistry to study its expression, distribution, and post-translational modifications. These antibodies also facilitate research into adiponectin's signaling pathways, receptor interactions, and therapeutic potential. Polyclonal antibodies offer broad epitope recognition, while monoclonal antibodies provide high specificity, enabling precise detection of adiponectin isoforms. Validation across species (e.g., human, mouse, rat) ensures cross-reactivity in preclinical models. Given adiponectin's dual role in metabolism and inflammation, ADIPOQ antibodies remain vital for elucidating its pathophysiological mechanisms and developing diagnostic or therapeutic strategies targeting metabolic disorders.